Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor.

Abstract

BACKGROUND:

Hemolytic uremic syndrome is a rare multisystem disorder that is caused by infections, preeclampsia, autoimmune disorders, or oral contraceptive agents, and rarely in association with different cancers and chemotherapeutic agents.

CASE:

A 34-year-old woman who presented for evaluation of a pelvic mass received a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage 1c endodermal sinus tumor at laparotomy. Three months after receiving 3 courses of bleomycin, etoposide, and cisplatinum, she presented with renal failure, thrombocytopenia, anemia, and severe hypertension. Cancer-associated hemolytic uremic syndrome was diagnosed, and the patient was treated with plasmaphoresis, blood transfusion, and hemodialysis.

CONCLUSION:

Cancer-associated hemolytic uremic syndrome has a high mortality rate; thus, prompt diagnosis is critical to survival.

• Authors: Dele A Ogunleye, Sharyn N Lewin, David G Mutch, Helen Liapis, Thomas J Herzog
• Journal: Obstetrics and gynecology (Obstet Gynecol) Vol. 104 Issue 5 Pt 2 Pg. 1184-7 (Nov 2004) ISSN: 0029-7844 [Print] United States
• PMID: 15516446 (Publication Type: Case Reports, Journal Article)

Topics

• Abdominal Pain (diagnosis, etiology)
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Biopsy, Needle
• Blood Transfusion
• Chemotherapy, Adjuvant (adverse effects)
• Combined Modality Therapy
• Endodermal Sinus Tumor (pathology, therapy)
• Female
• Follow-Up Studies
• Hemolytic-Uremic Syndrome (chemically induced, physiopathology, therapy)
• Humans
• Immunohistochemistry
• Ovarian Neoplasms (pathology, therapy)
• Ovariectomy (methods)
• Plasmapheresis
• Renal Dialysis
• Risk Assessment
• Treatment Outcome